Abbrea Capital’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $5.62M | Sell |
45,139
-2,247
| -5% | -$289K | 0.74% | 31 |
|
|
2024
Q1 | $6.29M | Buy |
47,386
+235
| +0.5% | +$29K | 0.83% | 30 |
|
|
2023
Q4 | $5.18M | Buy |
47,151
+260
| +0.6% | +$27K | 0.74% | 33 |
|
|
2023
Q3 | $4.86M | Sell |
46,891
-10
| -0% | -$1.08K | 0.77% | 31 |
|
|
2023
Q2 | $5.45M | Buy |
46,901
+484
| +1% | +$55K | 0.84% | 28 |
|
|
2023
Q1 | $4.97M | Buy |
46,417
+360
| +0.8% | +$38.9K | 0.84% | 29 |
|
|
2022
Q4 | $5.14M | Buy |
46,057
+1,065
| +2% | +$109K | 0.93% | 29 |
|
|
2022
Q3 | $3.91M | Buy |
44,992
+358
| +0.8% | +$32K | 0.74% | 34 |
|
|
2022
Q2 | $4.1M | Sell |
44,634
-40
| -0.1% | -$3.55K | 0.68% | 35 |
|
|
2022
Q1 | $3.7M | Sell |
44,674
-720
| -2% | -$56.8K | 0.52% | 47 |
|
|
2021
Q4 | $3.51M | Buy |
45,394
+273
| +0.6% | +$21.7K | 0.47% | 49 |
|
|
2021
Q3 | $3.42M | Sell |
45,121
-1,100
| -2% | -$83.7K | 0.51% | 49 |
|
|
2021
Q2 | $3.62M | Sell |
46,221
-1,500
| -3% | -$112K | 0.54% | 48 |
|
|
2021
Q1 | $3.54M | Buy |
47,721
+1,672
| +4% | +$123K | 0.58% | 45 |
|
|
2020
Q4 | $3.62M | Sell |
46,049
-533
| -1% | -$40.8K | 0.65% | 38 |
|
|
2020
Q3 | $3.71M | Sell |
46,582
-1,242
| -3% | -$97.3K | 0.79% | 32 |
|
|
2020
Q2 | $3.56M | Buy |
47,824
+847
| +2% | +$63.8K | 0.81% | 32 |
|
|
2020
Q1 | $3.48M | Buy |
46,977
+135
| +0.3% | +$10.6K | 0.92% | 30 |
|
|
2019
Q4 | $4.09M | Sell |
46,842
-553
| -1% | -$45.4K | 0.87% | 33 |
|
|
2019
Q3 | $3.83M | Buy |
47,395
+4,522
| +11% | +$362K | 0.89% | 34 |
|
|
2019
Q2 | $3.45M | Buy |
42,873
+12,128
| +39% | +$929K | 0.85% | 36 |
|
|
2019
Q1 | $2.46M | Buy |
30,745
+261
| +0.9% | +$19.5K | 0.71% | 40 |
|
|
2018
Q4 | $2.24M | Buy |
30,484
+663
| +2% | +$46.8K | 0.74% | 42 |
|
|
2018
Q3 | $2.03M | Sell |
29,821
-1,364
| -4% | -$86.9K | 0.6% | 53 |
|
|
2018
Q2 | $1.82M | Sell |
31,185
-1,200
| -4% | -$67.7K | 0.57% | 54 |
|
|
2018
Q1 | $1.7M | Buy |
32,385
+742
| +2% | +$40.1K | 0.55% | 53 |
|
|
2017
Q4 | $1.71M | Sell |
31,643
-2,551
| -7% | -$141K | 0.58% | 54 |
|
|
2017
Q3 | $2.1M | Hold |
34,194
| – | – | 0.78% | 41 |
|
|
2017
Q2 | $2.11M | Buy |
34,194
+47
| +0.1% | +$2.86K | 0.84% | 39 |
|
|
2017
Q1 | $2.08M | Buy |
34,147
+528
| +2% | +$32K | 0.85% | 39 |
|
|
2016
Q4 | $1.89M | Buy |
+33,619
| New | +$1.97M | 0.89% | 35 |
|
Other funds holding MRK
Abbrea Capital's MRK Position: Q2 2024 in Review
Abbrea Capital reduced its Merck (MRK) stake by 4.7% in Q2 2024, selling an estimated $289K and leaving 45,139 shares worth $5.62M. The position accounts for 0.74% of the portfolio, ranked #31.
Abbrea Capital first reported a position in MRK in Q4 2016 and has held it in 31 quarters since. The position peaked at $6.29M in Q1 2024. 3,545 funds tracked by Wall St. Rank hold MRK as of Q2 2024.
- Abbrea Capital held 45,139 shares of Merck worth $5.62M as of Q2 2024.
- Abbrea Capital sold 2,247 Merck shares in Q2 2024, an estimated $289K.
- Merck made up 0.74% of Abbrea Capital's portfolio in Q2 2024, its #31 holding.
- Abbrea Capital first reported a position in Merck in Q4 2016 and has held it in 31 quarters since.
- Abbrea Capital's Merck position peaked at $6.29M in Q1 2024.
- 3,545 funds tracked by Wall St. Rank held Merck as of Q2 2024.
Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.